Congestive Heart Failure

Learning Objectives:

• Distinguish key differences between heart failure reduced ejection fraction and heart failure preserved ejection fraction.
• Devise an evidence-based treatment strategy for outpatients with heart failure reduced ejection fraction.
• Devise an evidence-based treatment strategy for outpatients with heart failure preserved ejection fraction.
• Devise an evidence-based treatment strategy for patients admitted to the cardiac intensive care for an acute heart failure exacerbation.
• Justify the role of anticoagulants in the management of venous thromboembolism prophylaxis for patients admitted for an acute heart failure exacerbation.
• Evaluate and adjust drug therapy regimens in patients receiving vasoactive therapies to optimize hemodynamics, volume status, and anticoagulation.
• Determine which high risk patient populations might be candidates for certain device therapies.

Online Module

The objective of this module is to provide an extensive review of the therapeutic approach to the treatment of congestive heart failure (CHF). This will include a therapeutic review of the treatment strategies of heart failure preserved ejection fraction (HFpEF) and heart failure reduced ejection fraction (HFrEF) including acute and chronic exacerbations.

Attendees completing this module will need to review the American College of Cardiology/American Heart Association Practice Guideline and Heart Failure Society of America guidelines (listed in the references below) prior to beginning the module questions. The other articles and reviews may be utilized for questions pertaining to drug class selections, dosages, indications, or other therapeutic treatments.